Ultragenyx Pharmaceutical | RARE - Gross Profit On Sales


Ultragenyx Pharmaceutical reported $106M in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
Acadia Pharmaceuticals USD 243.27M 14.49M Mar/2026
Agios Pharmaceuticals USD 19.43M 1.34M Mar/2026
Alnylam Pharmaceuticals USD 825M 4.3M Mar/2026
BioCryst Pharmaceuticals USD 153.05M 4.16M Dec/2025
BioMarin Pharmaceutical USD 571.21M 141.8M Mar/2026
Esperion Therapeutics USD 140.59M 94.57M Dec/2025
Immunic 0 0 Mar/2025
Insmed USD 256.46M 38.78M Mar/2026
Ionis Pharmaceuticals USD 243M 48M Mar/2026
Karyopharm Therapeutics USD 32.6M 63.38M Dec/2025
Kyowa Hakko Kirin JPY 88.25B 21.26B Mar/2026
MacroGenics USD 31.11M 30.14M Dec/2025
Moderna USD -566M 792M Mar/2026
Neurocrine Biosciences USD 800.7M 12.8M Mar/2026
PTC Therapeutics USD 232.94M 84.56M Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 2.94B 363.7M Mar/2026
Sarepta Therapeutics USD 621.34M 577.79M Mar/2026
Ultragenyx Pharmaceutical USD 106M 72M Mar/2026
Vertex Pharmaceuticals USD 2.6B 121.7M Mar/2026
Xoma 992K 846K Jun/2024